Back to top
more

Equillium (EQ)

(Real Time Quote from BATS)

$0.56 USD

0.56
7,109,191

-0.15 (-21.13%)

Updated Aug 4, 2025 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?

by Zacks Equity Research

Here is how Aveanna Healthcare (AVAH) and Equillium, Inc. (EQ) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Equillium (EQ) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Equillium (EQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of 3.33% and 230.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 0% and 4.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Equillium (EQ) delivered earnings and revenue surprises of 106.67% and 69.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of 9.09% and 2.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

5 Stocks That More Than Doubled in Q1 With More Gains Ahead

by Sweta Killa

Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.

Zacks Equity Research

Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of -5.88% and 99.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark

by Zacks Equity Research

Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark are included in this Analyst Blog.

Sweta Killa headshot

5 Stocks That More Than Doubled in February

by Sweta Killa

Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.

Zacks Equity Research

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -12.60% and 19.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

5 Top-Ranked Stocks That Have More Than Doubled Year to Date

by Sweta Killa

Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.

Zacks Equity Research

Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 47.37% and 6.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 45% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)

by Zacks Equity Research

Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

by Zacks Equity Research

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

Zacks Equity Research

Is Equillium (EQ) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (EQ) Outperforming Other Medical Stocks This Year?